We conducted a hospital-based case–control study to analyze the genotypes of resistin polymorphisms and explored their association with lung cancer risk, efficacy, and toxicity in lung cancer patients receiving platinum-based chemotherapy. This evidence concerns the gene RETN and lung carcinoma.